Boron tracedrug design for neutron dynamic therapeutics for LDL.

ABSTRACT

We describe our solution for removal of the low-density lipoprotein (LDL) depot contained in proteins and lipids as a 'druggable' target for atherosclerotic cardiovascular diseases by neutron dynamic therapy (NDT), which we developed using boron tracedrugs for NDT against bovine serum albumin as a model protein. Thus, we examined, among our developed boron tracedrugs, a boron-containing curcuminoid derivative UTX-51, to destroy freshly isolated human LDL dynamically under irradiated thermal neutron to obtain a decreased intensity of band of LDL treated with UTX-51 and thermal neutron irradiation in their SDS-PAGE and electrophoresis analysis. These results suggest that UTX-51 might be a novel candidate of 'beyond chemical' therapeutic agents for atherosclerotic cardiovascular disease.